Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY ...

Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold ...

The deal includes additional commercial milestone payments of up to $250 million and will be completed by year-end, subject ...

As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...

Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights ...

Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic ...

Kepler Capital analyst Niccolo Guido Storer maintained a Hold rating on Recordati Industria Chimica e Farmaceutica SPA (0KBS – Research ...

Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to ...

Recordati 's (BIT: RECI) shares jumped on Friday following its deal with Sanofi (NASDAQ: SNY) to buy the global rights to ...